Clicky

Allarity Therapeutics, Inc.(ALLR)

Description: Allarity Therapeutics A/S develops various therapeutic candidates for the treatment of cancer using drug-specific companion diagnostics (cDx) generated by its drug response predictor technology. Its lead therapeutic candidate is dovitinib, a second-generation pan-tyrosine kinase inhibitor with the ability to inhibit numerous classes of tumor-driving tyrosine kinases, including FGFR, VEGFR, PDGFR, c-Kit, Flt-3, and CSF-1. The company's therapeutic candidates also include stenoparib, selective inhibitor of the key DNA damage repair enzyme poly-ADP-ribose polymerase; and IXEMPRA, a selective microtubule inhibitor that interferes with cancer cell division through mitotic arrest. It also developing other therapeutic candidates comprising LiPlaCis, a targeted liposomal formulation of Cisplatin; 2X-111, a targeted liposomal formulation of Doxorubicin; and Irofulven, a DNA damaging agent. The company was founded in 2004 and is headquartered in Horsholm, Denmark.


Keywords: Cancer Drugs Health Sciences Treatment Of Cancer Enzymes Protein Kinase Inhibitor Tyrosine Kinase Doxorubicin Liposome

Home Page: www.allarity.com

ALLR Technical Analysis

210 Broadway
Cambridge, MA 02139
United States
Phone: 401 426 4664


Officers

Name Title
Mr. James G. Cullem J.D. Interim CEO, Chief Bus. Officer, Sr. VP of Corp. Devel. & Director
Dr. Marie Foegh DrSc, M.D. Chief Medical Officer
Mr. Peter Buhl Jensen Adj Professor, M.D., M.D., Ph.D., Ph.D. Co-Founder
Dr. Steen Meier Knudsen Ph.D. Founder & Chief Scientific Officer
Mr. Thomas H. Jensen Founder, Sr. VP of Investor Relations & Director
Mr. Claus Frisenberg Pedersen Chief Commercial Officer
Ms. Joan Brown Interim CFO & Director of Financial Reporting
Ms. Annie Rasmussen Chief of Clinical Operations

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 2.659
Price-to-Sales TTM: 0
IPO Date: 2021-12-21
Fiscal Year End: December
Full Time Employees: 13
Back to stocks